Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Cardiac Failure

• Publication date

  2003-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1071-9164(03)00582-7PMID 14966787
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The nutrition implications of cardiac cachexia.

  2009cited by this paper
• Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure

  2003cited by this paper
• Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity.

  2003cited by this paper
• Prevention and reversal of cachexia in patients with chronic heart failure by bisoprolol: Results from the CIBIS-II study

  2003cited by this paper
• The prognostic value of body mass index and standard exercise testing in male veterans with congestive heart failure.

  2002cited by this paper
• Neurohormonal factors in the development of catabolic/anabolic imbalance and cachexia.

  2002cited by this paper
• Nutritional abnormalities contributing to cachexia in chronic illness.

  2002cited by this paper
• Chronic heart failure: an example of a systemic chronic inflammatory disease resulting in cachexia.

  2002cited by this paper
• Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failure.

  2002cited by this paper
• The syndrome of cardiac cachexia.

  2002cited by this paper
• American Heart Association 2001 Scientific Sessions

  2001cited by this paper
• Hypothesis: β-Adrenergic Receptor Blockers and Weight Gain

  2001cited by this paper
• Effect of carvedilol on survival in severe chronic heart failure.

  2001cited by this paper
• Reversal of catabolism by beta-blockade after severe burns.

  2001cited by this paper
• Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis.

  2001cited by this paper
• Catabolism in chronic heart failure.

  2000cited by this paper
• Leptin serum levels in cachectic heart failure patients. Relationship with tumor necrosis factor-alpha system.

  2000cited by this paper
• Inappropriately low plasma leptin concentration in the cachexia associated with chronic heart failure

  1999cited by this paper
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

  1999cited by this paper
• The role of leptin in human physiology.

  1999cited by this paper
• Hyperleptinaemia in chronic heart failure. Relationships with insulin.

  1998cited by this paper
• Leptin and cardiac cachexia: marker or mediator?

  1998cited by this paper
• Wasting as independent risk factor for mortality in chronic heart failure.

  1997cited by this paper
• Isoproterenol and somatostatin decrease plasma leptin in humans: a novel mechanism regulating leptin secretion.

  1997cited by this paper
• Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia.

  1997cited by this paper
• Plasma leptin concentrations and energy expenditure in heart failure patients.

  1997cited by this paper
• The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

  1996cited by this paper
• Increased Resting Metabolic Rate in Patients with Congestive Heart Failure

  1994cited by this paper
• Cardiac cachexia.

  1991cited by this paper
• Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.

  1990cited by this paper
• The Pathogenesis of Cardiac Cachexia

  1964cited by this paper

• Heart failure decreases adipocyte progenitors with impaired differentiation capacity toward mature adipocytes.

  2025cites this paper
• Vascular Dysfunction in Cardiac Cachexia: Molecular Mechanisms and Pharmacotherapies

  2025cites this paper
• Metabolic pathways for removing reactive aldehydes are diminished in the skeletal muscle during heart failure

  2024cites this paper
• Controversies and Conundrums in Cardiac Cachexia: Key Questions About Wasting in Patients With HFrEF.

  2024cites this paper
• Diagnosis and Management of Malnutrition in Patients with Heart Failure

  2023cites this paper
• Metabolic Pathways for Removing Reactive Aldehydes are Diminished in Atrophic Muscle During Heart Failure

  2023cites this paper
• The Role of Sarcopenia in Heart Failure with Depression

  2022cites this paper
• Interconnection between Cardiac Cachexia and Heart Failure—Protective Role of Cardiac Obesity

  2022cites this paper
• Relevance of nutritional assessment and treatment to counteract cardiac cachexia and sarcopenia in chronic heart failure.

  2021cites this paper
• Sarcopenia in Other Settings: Primary Care, Cardiovascular Disease, Surgery

  2021cites this paper
• Sarcopenia and Heart Failure

  2020cites this paper
• Pharmacological management of cardiac cachexia: a review of potential therapy options

  2019cites this paper
• Sympathetic overactivation predicts body weight loss in patients with heart failure.

  2019cites this paper
• Evaluation of the effect of cholesterol supplementation on experimental pulmonary arterial hypertension

  2018cites this paper
• Leptin-Aldosterone-Neprilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity

  2018cites this paper
• Palliative Care in Heart Failure

  2018cites this paper
• Effekte pharmakologischer Interventionen auf Muskelatrophie im Mausmodell der amyotrophen Lateralsklerose (ALS)

  2017cites this paper
• Muscle wasting and cachexia in heart failure: mechanisms and therapies

  2017cites this paper
• Effect of Beta-blocker Treatment on V˙O2peak in Patients with Heart Failure

  2017cites this paper
• Central TrkB blockade attenuates ICV angiotensin II-hypertension and sympathetic nerve activity in male Sprague-Dawley rats.

  2017cites this paper
• Cardiac cachexia – Up-to-date 2015

  2016cites this paper
• Sarcopenia in heart failure: mechanisms and therapeutic strategies

  2016cites this paper
• Common Medications Which Lead to Unintended Alterations in Weight Gain or Organ Lipotoxicity

  2015cites this paper
• Interaction between Angiotensin II and BDNF in Modulating Sympathetic Nerve Activity

  2015cites this paper
• Molecular mechanisms and treatment targets of muscle wasting and cachexia in heart failure: an overview

  2014cites this paper
• Influencia pronóstica del estado nutricional en el paciente con insuficiencia cardiaca

  2013cites this paper
• Cardiorenal syndrome: pathophysiology and potential targets for clinical management

  2013cites this paper
• Cachexia and sarcopenia: emerging syndromes of importance in dogs and cats.

  2012cites this paper
• Nutritional issues in heart transplant candidates and recipients.

  2012cites this paper
• The beta-1 adrenergic antagonist, atenolol, decreases acylation stimulating protein, exercise capacity and plasma free fatty acids in men with type 2 diabetes.

  2012cites this paper
• Molecular mechanisms of cachexia in chronic disease

  2012cites this paper
• Beta-blockers and weight change in patients with chronic heart failure.

  2012cites this paper
• High dose ascorbic acid does not reverse central sympathetic overactivity in chronic heart failure

  2011cites this paper
• Pathophysiology and Treatment Options for Cardiac Anorexia

  2011cites this paper
• Inhibition of sympathetic activity and modulation of insulin resistance in cardiovascular disease.

  2011cites this paper
• [Chronic heart failure, nutritional status and survival].

  2011cites this paper
• Der Einfluss von Bisoprolol und IGF-1 als alleinige Medikation und in Kombination auf Gewichtsverlauf, Körperzusammensetzung, spontane Aktivität und Herzfunktion in einem Rattenmodell der Tumor-Kachexie

  2011cites this paper
• Alterations in Nutrition and Body Mass in Heart Failure

  2011cites this paper
• Cardiac Cachexia in Chronic Heart Failure: The Metabolic Facet of CHF

  2010cites this paper
• Sympathoinhibition by atorvastatin in hypertensive patients.

  2010cites this paper
• Der Einfluss der Xanthinoxidasehemmer Allopurinol und Oxypurinol auf Gewichtsverlauf, Körperzusammensetzung und spontane Aktivität in einem Rattenmodell der Tumorkachexie

  2010cites this paper
• Body mass, chronic heart failure, surgery and survival.

  2010cites this paper
• Gastrointestinal symptoms in end-stage heart failure

  2010cites this paper
• Adipose tissue secreted factors in specific populations and metabolic states : implications for energy balance and metabolic health

  2010cites this paper
• End-of-life care in heart failure

  2009cites this paper
• Nutrition and heart failure: impact of drug therapies and management strategies.

  2009cites this paper
• Cardiac cachexia: a systematic overview.

  2009cites this paper
• Chronic heart failure and skeletal muscle myopathy: Effects of exercise training

  2009cites this paper
• Animal models of anorexia and cachexia

  2009cites this paper
• Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure.

  2008cites this paper
• Efeito do uso de carvedilol no sistema nervoso simpático de pacientes submetidos à hemodiálise

  2008cites this paper
• Heart failure and cachexia: insights offered from molecular biology.

  2008cites this paper
• The nature of cachexia in patients with heart failure and stable coronary artery disease

  2007cites this paper
• Pharmacological treatment of geriatric cachexia: evidence and safety in perspective.

  2007cites this paper
• Effect of selective and non-selective β-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure

  2007cites this paper
• Body composition changes in patients with systolic heart failure treated with beta blockers: a pilot study.

  2006cites this paper
• Prognosis and therapy approaches of cardiac cachexia

  2006cites this paper
• Cachexia in Cardiovascular Illness

  2006cites this paper
• Symptom Control in Palliative Care—Part II: Cachexia/Anorexia and Fatigue

  2006cites this paper
• [Cardiac cachexia].

  2006cites this paper
• Treatment of Cachexia in the Elderly

  2006cites this paper
• Metabolic and immunologic derangements in cardiac cachexia: where to from here?

  2006cites this paper
• Pathophysiology of peripheral muscle wasting in cardiac cachexia

  2005cites this paper
• Muscle wasting in cardiac cachexia.

  2005cites this paper
• Cachexia in chronic heart failure: Prognostic implications and novel therapeutic approaches

  2005influential citation
• Sympathetic modulation by carvedilol and losartan reduces angiotensin II-mediated lipolysis in subcutaneous and visceral fat.

  2005cites this paper
• Cardiac Cachexia — Drugs in Clinical Use

  2005cites this paper
• Cardiac Cachexia: Is it Time to Legalise Anabolic Agents?

  2004cites this paper